$33.77
0.78% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US92337F1075
Symbol
VCYT
Sector
Industry

Veracyte Inc Stock price

$33.77
+1.77 5.53% 1M
+12.05 55.48% 6M
+6.26 22.76% YTD
+10.91 47.73% 1Y
-13.91 29.17% 3Y
+9.54 39.37% 5Y
+24.04 247.07% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.26 0.78%
ISIN
US92337F1075
Symbol
VCYT
Sector
Industry

Key metrics

Market capitalization $2.57b
Enterprise Value $2.36b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 58.78
EV/Sales (TTM) EV/Sales 5.90
P/S ratio (TTM) P/S ratio 6.44
P/B ratio (TTM) P/B ratio 2.27
Revenue growth (TTM) Revenue growth 21.59%
Revenue (TTM) Revenue $399.58m
EBIT (operating result TTM) EBIT $7.42m
Free Cash Flow (TTM) Free Cash Flow $40.13m
Cash position $235.92m
EPS (TTM) EPS $-0.74
P/E forward 148.44
P/S forward 5.90
EV/Sales forward 5.41
Short interest 5.08%
Show more

Is Veracyte Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Veracyte Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Veracyte Inc forecast:

7x Buy
78%
1x Hold
11%
1x Sell
11%

Analyst Opinions

9 Analysts have issued a Veracyte Inc forecast:

Buy
78%
Hold
11%
Sell
11%

Financial data from Veracyte Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
400 400
22% 22%
100%
- Direct Costs 144 144
8% 8%
36%
255 255
31% 31%
64%
- Selling and Administrative Expenses 159 159
6% 6%
40%
- Research and Development Expense 63 63
37% 37%
16%
32 32
3,511% 3,511%
8%
- Depreciation and Amortization 25 25
17% 17%
6%
EBIT (Operating Income) EBIT 7.42 7.42
124% 124%
2%
Net Profit -54 -54
86% 86%
-14%

In millions USD.

Don't miss a Thing! We will send you all news about Veracyte Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Veracyte Inc Stock News

Neutral
Business Wire
12 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--New Data Presented at ESMO 2024 Show that Veracyte's Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer.
Neutral
Business Wire
23 days ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--Veracyte appoints Brent Shafer and Tom Miller, Ph.D., to its board of directors.
Neutral
Business Wire
about one month ago
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Thursday, September 5, at 2:35 p.m. Eastern Time. A live audio webcast of the company's presentation will be ava...
More Veracyte Inc News

Company Profile

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Head office United States
CEO Marc Stapley
Employees 815
Founded 2006
Website www.veracyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today